| 8.51 -6.16 (-41.99%) | 06-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 18.19 |
1-year : | 23.44 |
| Resists | First : | 15.57 |
Second : | 20.07 |
| Pivot price | 14.82 |
|||
| Supports | First : | 8.3 |
Second : | 6.9 |
| MAs | MA(5) : | 13.43 |
MA(20) : | 15.28 |
| MA(100) : | 19.82 |
MA(250) : | 28.28 |
|
| MACD | MACD : | -1.2 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 14.9 |
D(3) : | 16.8  |
| RSI | RSI(14): 17.3 |
|||
| 52-week | High : | 46.58 | Low : | 8.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNWV ] has closed below the lower bollinger band by 35.9%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ SNWV ] is to continue within current trading range. It is unclear right now based on current values. 76.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10 - 10.07 | 10.07 - 10.13 |
| Low: | 8.19 - 8.25 | 8.25 - 8.29 |
| Close: | 8.43 - 8.52 | 8.52 - 8.6 |
SANUWAVE Health, Inc. is a company dedicated to the research, development, and commercialization of non-invasive, high-energy acoustic shockwave technology. Operating both domestically and internationally, the firm applies these shockwaves in regenerative medicine and other therapeutic areas. The underlying principle involves stimulating a biological response within the body, prompting self-healing through the restoration and growth of tissues, musculoskeletal structures, and vascular networks. Its flagship regenerative product is the dermaPACE device, specifically engineered for treating diabetic foot ulcers. The company's diverse range of healthcare solutions and pipeline products are designed to trigger vital biologic signaling and angiogenic responses, such as fostering new vascularization and improving microcirculation, ultimately revitalizing the body's natural healing and regenerative capabilities. SANUWAVE also utilizes its proprietary Pulsed Acoustic Cellular Expression (PACE) technology across various medical fields, including wound healing, orthopedics, plastic/cosmetic applications, and cardiac conditions. Beyond its core shockwave offerings, the company provides the UltraMIST device, a non-contact, non-thermal ultrasound therapy for managing conditions like diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. Additionally, its orthoPACE system addresses tendinopathies and both acute and nonunion fractures. Established in 2005, SANUWAVE Health, Inc. is based in Suwanee, Georgia.
Tue, 16 Jun 2026
Sanuwave updates Q2 revenue guidance to $8.5–$9.5M, applicator demand strong despite Ultramist headwinds - TradingView
Thu, 11 Jun 2026
SNWV: Director elections, auditor ratification, and executive pay were voted on; results pending - TradingView
Thu, 21 May 2026
Shareholders Shouldn’t Be Too Comfortable With SANUWAVE Health's (NASDAQ:SNWV) Strong Earnings - simplywall.st
Wed, 13 May 2026
SANUWAVE Health Inc Reports Q1 2026 Results: Full Earnings Call Transcript - Yahoo Finance
Tue, 12 May 2026
Sanuwave Health Inc. (SNWV) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Mon, 04 May 2026
Opaleye management sells $574,240 of SANUWAVE Health (SNWV) stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 47.2 (%) |
| Shares Short | 782 (K) |
| Shares Short P.Month | 768 (K) |
| EPS | 0.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.18 |
| Profit Margin | 37.2 % |
| Operating Margin | -11.7 % |
| Return on Assets (ttm) | 8.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 3 % |
| Gross Profit (p.s.) | 3.95 |
| Sales Per Share | 5.15 |
| EBITDA (p.s.) | 0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 6 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 8.86 |
| PEG Ratio | 0 |
| Price to Book value | 44.78 |
| Price to Sales | 1.65 |
| Price to Cash Flow | 12.64 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|